| Literature DB >> 35203656 |
Hideya Kawasaki1, Hiromi Suzuki1, Kazuki Furuhashi2, Keita Yamashita2, Jinko Ishikawa2, Osanori Nagura2, Masato Maekawa2, Takafumi Miwa3, Takumi Tandou4, Takahiko Hariyama1,5.
Abstract
The gold standard test for identifying SARS-CoV-2, the causative agent of COVID-19, is polymerase chain reaction (PCR). Despite their limited sensitivity, SARS-CoV-2 antigen rapid diagnostic tests are vital tools in the fight against viral spread. Owing to its simplicity and low cost, the lateral flow assay (LFA) is the most extensively used point-of-care diagnostic test. Here, we report a newly designed LFA-NanoSuit method (LNSM) that works in conjunction with desktop scanning electron microscopy (SEM) to detect SARS-CoV-2. LNSM requires no standard SEM treatment, avoids cellulose and residual buffer deformation, and enables the capture of high-resolution images of antibody-labeled gold/platinum particles reacting with SARS-CoV-2 antigens. To assess its applicability, we compared clinical SARS-CoV-2 samples via visual detection of LFA, LSNM detection of LFA, and real-time reverse transcription-PCR (qRT-PCR). Compared to qRT-PCR, LNSM showed 86.7% sensitivity (26/30; 95% confidence interval (CI): 69.28-96.24%) and 93.3% specificity (14/15; 95% CI: 68.05-99.83%) for SARS-CoV-2. In samples with a relatively low SARS-CoV-2 RNA copy number (30 < Ct ≤ 40), the sensitivity of LNSM was greater (73.3%) than that of visual detection (0%). A simple, sensitive, and quantitative LNSM can be used to diagnose SARS-CoV-2.Entities:
Keywords: COVID-19; NanoSuit; SARS-CoV-2; desktop scanning electron microscopy; lateral flow assay
Year: 2022 PMID: 35203656 PMCID: PMC8962435 DOI: 10.3390/biomedicines10020447
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059